JAMA Network
What The Study Did: This analysis of more than 31,000 compassionate use requests for unlicensed products for patients with serious medical conditions examined the disparities in access observed across countries and the key factors.
Authors: Paul Aliu, Pharm.D., M.R.Pharm.S., G.Dip. (Law), M.B.A., of Novartis Pharma AG in Basel, Switzerland, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamahealthforum.2022.0475)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
